Download Full Text (369 KB)
Hyperactivity is a shared behavior with ASD and Attention Deficit Hyperactivity Disorder (ADHD). Medications such as Methylphenidate (MPH) and α 2-a adrenergic receptor agonists are used to modify hyperactivity behavior in ADHD and thus have been used as management in ASD. A review of literature was done to evaluate the use of medications typically used for ADHD in the use of ASD. The databases searched included PubMED, PsycINFO, Cochrane, and Clinical Key. After reviewing the literature, it was found that both MPH and 2-a adrenergic receptor agonist have a potential role in pharmacotherapy for ASD. MPH may be slightly more effective at reducing hyperactivity-impulsivity behaviors than 2-a adrenergic receptor agonist, however the side effect profile in MPH has led to more discontinuations over 2-a adrenergic receptor agonist. More studies would need to be conducted to validate the findings of this review.
Physician Assistant Studies
Date of Work
ASD, ADHD, PDD-NOS, Asperger syndrome, autistic disorder, Hyperactivity, Stimulants, MPH, Guanfacine, Clonidine
Medicine and Health Sciences
Katnis, Jenna, "Pharmacotherapy for Impulsivity-hyperactivity behaviors in autism spectrum disorder" (2019). Physician Assistant Scholarly Project Posters. 193.